Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cassava Sciences Inc

1.61
-0.0100-0.62%
Post-market: 1.60-0.0100-0.62%19:57 EDT
Volume:435.09K
Turnover:707.13K
Market Cap:77.78M
PE:-1.10
High:1.67
Open:1.64
Low:1.60
Close:1.62
Loading ...

Cassava Sciences Inc. Announces New Clinical Study for Simufilam as Potential Treatment for TSC-Related Epilepsy

Reuters
·
01 May

Cassava Appoints Angélique Bordey, PhD, to Enhance Preclinical Program in TSC

GlobeNewswire
·
01 May

Cassava Sciences CMO James Kupiec to Retire

MT Newswires Live
·
22 Apr

Cassava Sciences Chief Medical Officer Kupiec Retires

Dow Jones
·
22 Apr

Cassava Sciences Announces Leadership Changes Amid Strategic Shift

TIPRANKS
·
22 Apr

Cassava Sciences chief medical officer James Kupiec to retire

TIPRANKS
·
22 Apr

Cassava Announces Retirement of Chief Medical Officer, DR. Jim Kupiec, and Appointment of DR. Jack Moore as Senior Vice President, Clinical Development

THOMSON REUTERS
·
22 Apr

Press Release: Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development

Dow Jones
·
22 Apr

Down -39.52% in 4 Weeks, Here's Why Cassava Sciences (SAVA) Looks Ripe for a Turnaround

Zacks
·
01 Apr

Is the Future Bleak for SAVA Stock Following Another Setback?

Zacks
·
31 Mar

Cassava Sciences must face malicious prosecution lawsuit over Alzheimer's drug

Reuters
·
27 Mar

SAVA Stock Down as Alzheimer's Drug Fails in Second Late-Stage Study

Zacks
·
26 Mar

Equity Markets Close Higher, Weak Consumer Confidence Data Lifts Fed Easing Hopes

MT Newswires Live
·
26 Mar

Top Midday Decliners

MT Newswires Live
·
26 Mar

Cassava Sciences Price Target Maintained With a $2.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties

TIPRANKS
·
25 Mar

Cassava Sciences Stock Falls as Alzheimer Drug Misses Targets, To Be Discontinued

Dow Jones
·
25 Mar

Cassava Sciences Shares Drop 21% After Co to Discontinue Development of Alzheimer's Disease Drug

THOMSON REUTERS
·
25 Mar

BUZZ-Cassava falls after stopping development of Alzheimer's drug

Reuters
·
25 Mar

Cassava Sciences' Phase 3 Study of Simufilam Showed No Benefit for Alzheimer's Patients

MT Newswires Live
·
25 Mar